Your session is about to expire
← Back to Search
Chemotherapy + Anakinra for Pancreatic Cancer
Study Summary
This trial will test whether the addition of the drug anakinra to standard chemotherapy can improve outcomes for patients with pancreatic cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 & 3 trial • 104 Patients • NCT01809132Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function is within the normal range.I have not had major surgery or any vascular device placement in the last 2 weeks.I do not have any ongoing serious infections requiring treatment.I am HIV positive.I have an active hepatitis B or C infection.I am currently on medication that suppresses my immune system.I have a tumor in the cells that make insulin in my pancreas.I have had an organ transplant.My pancreatic cancer can potentially be removed with surgery.My liver tests are within the normal range.I am under 18 years old.My pancreatic cancer is at stage IV.I have not had serious heart issues like heart failure or heart attack in the last 6 months.I am allergic to the medication used in this study.I have moderate to severe numbness or tingling in my hands or feet.I have been treated with anakinra, canakinumab, or another IL-1 inhibitor.I am 18 years old or older.I am fully active or restricted in physically strenuous activity but can do light work.My pancreatic cancer is at an early to mid-stage (Stage I-III).My cancer is primarily pancreatic ductal adenocarcinoma.I have had chemotherapy or radiation for pancreatic cancer.My doctor has diagnosed me with serious liver cirrhosis.I haven't had cancer, except for skin or cervical cancer, in the last 5 years.
- Group 1: Anakinra plus Chemotherapy
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there a risk of serious side effects from using Anakinra?
"The safety of Anakinra falls in the middle of our 1-3 scale because, while there is data attesting to its safety, Phase 2 trials have yet to establish any efficacy."
Anakinra is most often used for what reason?
"Anakinra is frequently used to manage sjia, but it can also be an effective treatment for nomid, receptors, interleukin-1, and steroid responses."
Are we still taking patients for this experiment?
"This study is not admitting patients at this time. This information was last updated on June 8th, 2021. There are currently 806 other clinical trials for adenocarcinoma and 34 trials testing Anakinra that are actively recruiting patients."
How many test subjects are enrolling in this clinical trial?
"This trial is no longer enrolling patients. The study was originally posted on June 1st, 2021 and edited for the last time on June 8th, 2021. For other options, there are 806 trials related to adenocarcinoma and 34 studies involving Anakinra that are still recruiting participants."
What other drug studies has Anakinra been a part of in the past?
"At this moment, there are 34 ongoing clinical trials studying Anakinra. Out of those, 6 have progressed to the third and final stage. Many of these experiments originated in Paris but have since spread to 440 different locations."
Share this study with friends
Copy Link
Messenger